Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

Video

In Partnership With:

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

Apalutamide has become the first drug approved in patients with nonmetastatic CRPC. This approval was based on the phase III SPARTAN trial in which apalutamide reduced the risk of metastasis or death by 72% in this patient population. The median metastasis-free survival was 40.5 months in the apalutamide arm versus 16.2 months in the placebo arm (HR, 0.28; 95% CI, 0.23-0.35; P <.0001).

Gomella says that this is a tremendous breakthrough in urologic oncology, which has been a great unmet need. Offering apalutamide to patients can hopefully extend their survival by delaying metastases, Gomella adds.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD